Welcome to the International Dermatology Outcome Measures
International Dermatology Outcome Measures is a non-profit organization seeking to develop and validate measures throughout dermatology with an initial focus on psoriatic disease. IDEOM strives for the establishment of patient-centric outcomes to enhance the research and treatment of dermatological conditions. Launched in 2013, IDEOM seeks to bring together physicians, researchers, government agencies, pharmaceutical companies, payers and patients from around the globe to develop and validate measures throughout the field of dermatology with an initial focus on psoriasis.
The group's inaugural meeting in Boston established a need for consistent core measurements when evaluating clinical trials and therapeutic effectiveness. At the second meeting in Toronto, the group began discussing what elements are critical to be measured in psoriatic clinical trials and in clinical practice. The third meeting focused on what patients and European regulators were interested in seeing in measures.
To become a stakeholder with IDEOM, participation in Delphi survey's, web conferences, workgroups, and in-person meetings will be required. PLEASE APPLY HERE
2019 IDEOM Annual Meeting: Save the Dates!
Patient Meeting: Thursday, May 16, 2019
Annual Meeting: Friday, May 17 - Saturday, May 18, 2019
Location: At the BRAND NEW Hilton Washington DC National Mall
480 L'Enfant Plaza SW I Washington, DC 20024 I USA
Details coming soon!
In the News
Academy, IDEOM Reach Consensus On Provider-Assessed Global Disease Severity Metric For Inflammatory Dermatoses.
Dermatology Advisor (11/21, Jacobs) reports that "the International Dermatology Outcome Measures (IDEOM) group and the American Academy of Dermatology (AAD) have arrived at a consensus on the development of a valid feasible provider-assessed global disease severity metric to be incorporated into a quality measure for inflammatory dermatoses." The article explains that "a total of 36 members from IDEOM and the AAD participated in the meeting, including dermatologists, pediatric dermatologists, rheumatologist-dermatologists, quality measures experts, members of the AAD, a patient, and a research fellow." The article adds that "in order to inform the modified Delphi process, a literature review was conducted and data were collected on current provider-assessed global disease severity metrics, with the results published in the Journal of the American Academy of Dermatology."
IDEOM featured in Dermatology Daily August 3, 2018. Read more....
IDEOM published in the Journal of Investigative Dermatology:Joseph F. Merola, David A. Amato, Kyoungah See, Russel Burge, Craig Mallinckrodt, Clement K Ojeh, Alice Gottlieb: Evaluation of sPGAxBSA as an outcome measure and treatment target for clinical practice. J. Invest. Dermatol. J Invest Dermatol. 2018 Mar 22. pii: S0022-202X(18)31741-X. doi: 10.1016/j.jid.2018.01.041. [Epub ahead of print]; 138:1955-1961. 2018.
President Alice Gottlieb received the 2018 "Excellence in Leadership Award" from the National Psoriasis Foundation for her work in psoriasis and psoriatic arthritis;June 7, 2018, NY, NY
Dr. April Armstrong received the 2018 Research Achievement Award in Psoriasis from the American Skin Association.